On July 8, Kanghua Bio(300841) issued an announcement that the company reached an agreement with Chengdu Xinran Bochuang Biotechnology Co., Ltd. (Xinran Bochuang) and decided to terminate the research and development project on tuberculosis mRNA vaccine, and at the same time terminate the subsequent research and development cooperation on rabies mRNA vaccine and herpes zoster mRNA vaccine. This decision was made based on the company’s established independent R&D team for the mRNA technology platform and the completion of the transfer of collaborative R&D results, combined with the company’s overall business development plan. The announcement mentioned that Sinopharm has completed the relevant research on rabies mRNA vaccine and shingles mRNA vaccine, and delivered the results to the company, and the company has paid the corresponding amount; however, the tuberculosis mRNA vaccine project has not yet been launched and no expenses or work results have been generated. In the agreement to terminate ...
RNAi technology targets the core shortcomings of GLP-1 drugs by precisely regulating the expression of obesity-related genes. With the disruptive advantage of “reducing fat without losing muscle”, RNAi therapy is strongly challenging the “hegemony” of the GLP-1 market worth hundreds of billions! 01The wave of small nucleic acid therapy has arrived Small nucleic acid therapy, especially siRNA (small interfering RNA) technology, with its unique gene silencing mechanism and continuously innovative delivery technology, jointly promotes the expansion of treatment areas from rare diseases to chronic diseases, leading the third wave of innovation in the biomedicine field. From the technical principle, siRNA achieves precise gene silencing through the RNA interference (RNAi) mechanism. In its double-stranded structure, the guide strand (antisense strand) is loaded into the RISC complex and then specifically binds to the target mRNA and guides its degradation, thereby blocking the expression of pathogenic proteins; while the guest strand (sense strand) ...
Recently, the world’s first dual-antibody ADC drug BL-B01D1 independently developed by Baili Tianheng has made significant progress in the Phase III clinical trial for the treatment of locally advanced or metastatic nasopharyngeal carcinoma. The analysis results show that the drug has successfully reached the primary endpoint and may bring new treatment options for nasopharyngeal carcinoma patients. Nasopharyngeal carcinoma is a highly invasive and recurrent head and neck malignant tumor. Although immunotherapy and targeted therapy have made some progress in recent years, treatment options are still limited for patients with recurrent or metastatic nasopharyngeal carcinoma, especially those who have failed multiple lines of treatment. Baili Tianheng’s BL-B01D1 came into being in this context. With its unique innovative drug mechanism, it brings new ideas to the treatment of nasopharyngeal carcinoma. BL-B01D1 is an EGFR×HER3 dual-antibody ADC drug. Its design principle is to simultaneously target two key targets, epidermal growth factor receptor (EGFR) ...
The FDA has approved KalVista Pharmaceuticals’ Ekterly (sebetralstat) as the first and only oral on-demand treatment for hereditary angioedema (HAE) attacks in patients aged 12 years and older. According to the company, approval was based on results from the Phase III KONFIDENT trial (NCT05259917), which was the largest clinical study ever conducted in HAE. Results from the trial showed faster symptom relief and attack resolution among patients administered Ekterly compared to placebo, along with strong efficacy and a favorable safety profile.1 How does Ekterly Change the Treatment Landscape for HAE? “The FDA approval of Ekterly is a defining moment for people living with HAE,” said Ben Palleiko, CEO, KalVista, in a press release. “Ekterly enables people to treat attacks the moment symptoms begin, wherever they are. This approval affirms the strength of our science and deep commitment to the HAE community. I am profoundly grateful to the KalVista team for ...
GENEVA (AP) — Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year. Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months. The agency said that the decision is significant in part because it’s only the third time it has approved a treatment under a fast-track authorization process, in coordination with the World Health Organization, to help developing countries access needed treatment. The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...
Organiser: RX Japan Ltd. Time:March 10-12, 2026 address:1-5-102 Nanko-Kita, Suminoe-ku, Osaka, 559-0034 Japan Exhibition hall:Intex Osaka Product range: Medical Equipment: Medical electronic instruments, ultrasonic instruments, X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, etc.; disposable medical supplies, dressings, and hygienic materials, various surgical instruments. Medical Supplies: Medical electronic instruments, medical ultrasonic instruments, medical X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, operating room, emergency room, and consultation room equipment and appliances, diagnostic equipment and supplies, disposable medical supplies, medical dressings, and hygienic materials, various surgical instruments, medical health care equipment and supplies, traditional Chinese medical instruments and rehabilitation devices, hemodialysis equipment, anesthesia and respiratory equipment, etc.; home health care products, small home diagnostic, monitoring, and treatment instruments, rehabilitation and physiotherapy instruments and supplies, electronic medical instruments, dental tools, hospital office supplies, sports medicine supplies. ...
When it comes to weight-resistance exercise, you can choose free weights such as dumbbells or barbells. Or weight machines, which are often driven by cables or levers. You can use resistance bands or tubes to build strength. Or try pushups and pullups — old standbys that create muscle overload by using your own body weight. These four basic options for strength training present fitness possibilities for young or old or beginners. And they offer flexibility for use in the gym, your home or in a hotel room during travel. You’ll probably wind up using a combination of the four, and they all have their pros and cons. They are appropriate for all ages and can be augmented with aerobic exercises like walking or running — or even climbing stairs. Let’s let Dr. Rafael Escamilla, a biomechanist and physical therapist at Sacramento State University in California, and Dr. Michael Stone, a ...
SUNDAY, July 6, 2025 (HealthDay News) — Alkaline. Electrolyte. Flavored. Walk down the beverage aisle and you’ll find all kinds of waters promising extra health perks. But are these fancy waters really better for you? Not really, Tufts University experts say. “There’s no physiological basis that there’s some metabolic benefit to these specialty waters over just regular, plain old water,” said Roger Fielding, a senior scientist at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts in Boston. For most people, Fielding said the best thing to do is simply drink more fluids — especially since many people walk around mildly dehydrated. “If you have a preference for a beverage and that’s going to make you drink more and you’ll be more attentive to rehydrating with that beverage, and you have the resources to purchase that beverage, well have at it,” Fielding said in a news release. ...
Drugdu.com expert’s response: Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with significant glucose-lowering effects, particularly suitable for patients with type 2 diabetes mellitus. Its specific manifestations are as follows: I. Core Glucose-Lowering Mechanisms Promotion of Insulin Secretion: By mimicking the body’s natural GLP-1, dulaglutide activates GLP-1 receptors, increasing cyclic adenosine monophosphate (cAMP) levels in pancreatic β-cells. This precisely stimulates insulin secretion when blood glucose levels rise (e.g., after meals), thereby lowering blood glucose. Inhibition of Glucagon Release: Glucagon is a hormone that raises blood glucose. Dulaglutide suppresses its secretion, further reducing hepatic glucose output and aiding in glycemic control. Delay of Gastric Emptying: By slowing the passage of gastric contents into the small intestine, dulaglutide prolongs carbohydrate absorption time, preventing sharp postprandial blood glucose spikes and achieving stable glycemic control. II. Clinical Efficacy Data Significant Reduction in Glycated Hemoglobin (HbA1c): Multiple studies demonstrate that after 24 weeks of dulaglutide treatment, HbA1c levels decrease by ...
Organiser: Poznań International Exhibition Company Time:May 19-20, 2026 address:Głogowska 14, 60-734 Poznań, Poland Exhibition hall:Poznan International Fair MTP Product range: Medical Devices: Medical equipment and instruments, medical rescue and emergency pharmaceutical special vehicles, equipment and instruments, laboratory equipment, rehabilitation and physiotherapy equipment, healthcare facility construction technology, medical communication equipment, and information technology. Medical Supplies and Services: Disposable materials, medical sterilization, cleaning, and disposal, as well as medical-related services. About SALMED: The Poland Poznań Medical Equipment Exhibition (SALMED) is Poland’s most significant exhibition for medical devices and instruments. Established in 1973, it is also one of the largest medical equipment and instrument exhibitions in Central and Eastern Europe and a key recommended event by the Polish Chamber of Exhibition Industry.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.